AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead CaseAccesswire • 06/11/24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmGlobeNewsWire • 06/11/24
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHGlobeNewsWire • 06/11/24
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROAccesswire • 06/09/24
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024GlobeNewsWire • 06/08/24
AKRO: Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. – Contact Kessler Topaz Meltzer & Check, LLPAccesswire • 06/07/24
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKROGlobeNewsWire • 06/07/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 06/07/24
AKRO: Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. - Contact Kessler Topaz Meltzer & Check, LLPAccesswire • 06/06/24
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsPRNewsWire • 06/06/24
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. – AKROGlobeNewsWire • 06/06/24
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROPRNewsWire • 06/05/24
AKRO STOCKHOLDERS - Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class ActionGlobeNewsWire • 06/05/24
IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmPRNewsWire • 06/05/24
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsGlobeNewsWire • 06/05/24
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmGlobeNewsWire • 06/05/24
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASHInvestors Business Daily • 06/05/24
Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.PRNewsWire • 06/04/24
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKROGlobeNewsWire • 06/03/24
AKRO INVESTOR ALERT: Kirby McInerney LLP Notifies Akero Therapeutics, Inc. (AKRO) Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitBusiness Wire • 06/03/24
Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.Accesswire • 06/02/24
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)Business Wire • 06/01/24
AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action LawsuitAccesswire • 05/31/24
ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROPRNewsWire • 05/29/24
